Oklahoma City, OK, United States of America

Rodger P McEver

This inventor holds 33 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 3 EPO patents, primarily in Inflammatory Disease Treatment. Top assignees: University of Oklahoma, Oklahoma Medical Research Foundation, Selexys Pharmaceuticals Corporation. Active years: 1991-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Rodger P McEver. Retrieved from https://idiyas.com/inventor/rodger-p-mcever

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 33 (Patent Applications = 3)

% Patents Active = 69.7

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 4)

Average Co-Inventor Count = 2.1

ph-index = 14

Forward Citations = 658(Granted Patents)

Company Filing History:

20 out of 576

University of Oklahoma

patents

10 out of 200

Oklahoma Medical Research Foundation

patents

4 out of 5

Selexys Pharmaceuticals Corporation

Southpac Trust International Inc.

patents

6. 1 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 1991-2020

Loading Chart...

Areas of Expertise:

Anti-P-Selectin Antibodies

Glycosulfopeptides

Stem Cells

Fucosylation

Inflammatory Conditions

Thrombotic Conditions

Hematopoietic Stem Cells

Peptide Inhibitors

Reperfusion Injury

Selectin Mediated Inflammation

Glycoprotein Ligand

Imaging Atherosclerotic Plaque

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10799538 - Cells treated by in vitro fucosylation and methods of production and use thereof (2020-10-13),

2. 9556266 - Methods of treating sickle cell disease with anti-P-selectin antibodies (2017-01-31),

3. 9511095 - Cells treated by in vitro fucosylation and methods of production and use thereof (2016-12-06),

4. 9068001 - Anti-P-selectin antibodies (2015-06-30),

5. 8945565 - Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies (2015-02-03),

6. 8633021 - Stem cells treated by in vitro fucosylation and methods of use (2014-01-21),

7. 8377440 - Anti-P-selectin antibodies and methods of using the same to treat inflammatory diseases (2013-02-19),

8. 8084255 - Stem cells treated by in vitro fucosylation and methods of use (2011-12-27),

9. 7776591 - Hematopoietic stem cells treated by in vitro fucosylation and methods of use (2010-08-17),

10. 7470776 - Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof (2008-12-30),

11. 7332334 - Hematopoietic stem cells treated by in vitro fucosylation and methods of use (2008-02-19),

12. 7223845 - Synthetic glycosulfopeptides and methods of synthesis thereof (2007-05-29),

13. 7189828 - Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof (2007-03-13),

14. 6667036 - Methods of treatment using antibodies to P-selectin glycoprotein ligand (2003-12-23),

15. 6593459 - Synthetic glycosulfopeptides and methods of synthesis thereof (2003-07-15),

Title: The Innovative Journey of Rodger P McEver

Introduction: Rodger P McEver, a distinguished inventor hailing from Oklahoma City, OK (US), has made significant contributions to the field of innovation with his groundbreaking ideas and inventions.

Latest Patents: Rodger P McEver holds several patents in various industries, including a recent patent for a cutting-edge medical device that revolutionizes patient care.

Career Highlights: Throughout his illustrious career, Rodger P McEver has been recognized for his exceptional problem-solving skills and creativity, leading to the development of numerous successful products that have improved the lives of many.

Collaborations: Rodger P McEver has collaborated with top research institutions and leading companies to bring his inventions to life, showcasing his ability to work effectively in multidisciplinary teams.

Conclusion: Rodger P McEver's passion for innovation and dedication to creating impactful solutions highlight him as a visionary inventor whose work continues to inspire the next generation of innovators.

Profile summary based on public USPTO records.